肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Front Mol Neurosci：研究发现抗血管生成的通路或可成为成胶质细胞瘤的新靶点

2017-10-21 MedSci MedSci原创

成胶质细胞瘤NFAT5
关注

成胶质细胞瘤（GBM）是发生于成年人的最具侵袭性的原发性颅内肿瘤，由于高度血管化的形成导致患者预后较差。因此，抗血管生成治疗已成为GBM治疗的一种有希望的治疗策略。本研究中，研究人员发现，胶质瘤样本和GBM细胞系中激活的T细胞5（NFAT5）的转录因子核因子水平明显升高，与胶质瘤WHO分级呈正相关。敲除NFAT5可抑制GBM细胞驱动的血管生成。此外，长链非编码RNA SBF2反义RNA 1（SBF

成胶质细胞瘤（GBM）是发生于成年人的最具侵袭性的原发性颅内肿瘤，由于高度血管化的形成导致患者预后较差。因此，抗血管生成治疗已成为GBM治疗的一种有希望的治疗策略。

本研究中，研究人员发现，胶质瘤样本和GBM细胞系中激活的T细胞5（NFAT5）的转录因子核因子水平明显升高，与胶质瘤WHO分级呈正相关。敲除NFAT5可抑制GBM细胞驱动的血管生成。此外，长链非编码RNA SBF2反义RNA 1（SBF2-AS1）在神经胶质瘤样本中上调，敲低SBF2-AS1可损害GBM诱导的血管生成。NFAT5的下调在转录水平上降低了SBF2-AS1的表达。

此外，SBF2-AS1的敲低通过增强miR-338-3p对EGF样 domain multiple 7（EGFL7）的抑制作用而抑制GBM细胞驱动的血管生成。体内研究表明，NFAT5敲低和SBF2-AS1敲低的组合产生最小的异种移植物体积和最低的微血管密度。

总之，该研究结果表明，NFAT5/SBF2-AS1/miR-338-3p/EGFL7途径可能为胶质瘤抗血管生成治疗提供新的靶点。

原始出处：

Hai Yu, Jian Zheng, et al., Transcription Factor NFAT5 Promotes Glioblastoma Cell-driven Angiogenesis via SBF2-AS1/miR-338-3p-Mediated EGFL7 Expression Change. Front Mol Neurosci. 2017; 10: 301. Published online 2017 Sep 21. doi: 10.3389/fnmol.2017.00301

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1753311, encodeId=dc611e53311b2, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 17 22:43:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932957, encodeId=22b0193295e69, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55766, encryptionId=6b1255e66ba, topicName=抗血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Feb 22 22:43:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288234, encodeId=b427128823420, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364248, encodeId=4d69136424810, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389188, encodeId=40c41389188e7, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475854, encodeId=0aea14e585489, content=<a href='/topic/show?id=2bcee797732' target=_blank style='color:#2F92EE;'>#细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77977, encryptionId=2bcee797732, topicName=细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5e7252474, createdName=spoonycyy, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545642, encodeId=6b651545642d4, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55770, encryptionId=4dd155e701f, topicName=抗血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608413807146, createdName=12498bd5m20暂无昵称, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2018-09-17 hanhaisha2020

    #研究发现#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1753311, encodeId=dc611e53311b2, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 17 22:43:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932957, encodeId=22b0193295e69, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55766, encryptionId=6b1255e66ba, topicName=抗血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Feb 22 22:43:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288234, encodeId=b427128823420, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364248, encodeId=4d69136424810, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389188, encodeId=40c41389188e7, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475854, encodeId=0aea14e585489, content=<a href='/topic/show?id=2bcee797732' target=_blank style='color:#2F92EE;'>#细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77977, encryptionId=2bcee797732, topicName=细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5e7252474, createdName=spoonycyy, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545642, encodeId=6b651545642d4, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55770, encryptionId=4dd155e701f, topicName=抗血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608413807146, createdName=12498bd5m20暂无昵称, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2018-02-22 flyingeagle77

    #抗血管#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1753311, encodeId=dc611e53311b2, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 17 22:43:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932957, encodeId=22b0193295e69, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55766, encryptionId=6b1255e66ba, topicName=抗血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Feb 22 22:43:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288234, encodeId=b427128823420, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364248, encodeId=4d69136424810, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389188, encodeId=40c41389188e7, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475854, encodeId=0aea14e585489, content=<a href='/topic/show?id=2bcee797732' target=_blank style='color:#2F92EE;'>#细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77977, encryptionId=2bcee797732, topicName=细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5e7252474, createdName=spoonycyy, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545642, encodeId=6b651545642d4, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55770, encryptionId=4dd155e701f, topicName=抗血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608413807146, createdName=12498bd5m20暂无昵称, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-23 lsndxfj

    #新靶点#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1753311, encodeId=dc611e53311b2, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 17 22:43:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932957, encodeId=22b0193295e69, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55766, encryptionId=6b1255e66ba, topicName=抗血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Feb 22 22:43:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288234, encodeId=b427128823420, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364248, encodeId=4d69136424810, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389188, encodeId=40c41389188e7, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475854, encodeId=0aea14e585489, content=<a href='/topic/show?id=2bcee797732' target=_blank style='color:#2F92EE;'>#细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77977, encryptionId=2bcee797732, topicName=细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5e7252474, createdName=spoonycyy, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545642, encodeId=6b651545642d4, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55770, encryptionId=4dd155e701f, topicName=抗血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608413807146, createdName=12498bd5m20暂无昵称, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-23 lsndxfj

    #ROS#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1753311, encodeId=dc611e53311b2, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 17 22:43:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932957, encodeId=22b0193295e69, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55766, encryptionId=6b1255e66ba, topicName=抗血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Feb 22 22:43:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288234, encodeId=b427128823420, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364248, encodeId=4d69136424810, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389188, encodeId=40c41389188e7, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475854, encodeId=0aea14e585489, content=<a href='/topic/show?id=2bcee797732' target=_blank style='color:#2F92EE;'>#细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77977, encryptionId=2bcee797732, topicName=细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5e7252474, createdName=spoonycyy, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545642, encodeId=6b651545642d4, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55770, encryptionId=4dd155e701f, topicName=抗血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608413807146, createdName=12498bd5m20暂无昵称, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-23 ms1692212821629096

    #胶质细胞#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1753311, encodeId=dc611e53311b2, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 17 22:43:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932957, encodeId=22b0193295e69, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55766, encryptionId=6b1255e66ba, topicName=抗血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Feb 22 22:43:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288234, encodeId=b427128823420, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364248, encodeId=4d69136424810, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389188, encodeId=40c41389188e7, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475854, encodeId=0aea14e585489, content=<a href='/topic/show?id=2bcee797732' target=_blank style='color:#2F92EE;'>#细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77977, encryptionId=2bcee797732, topicName=细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5e7252474, createdName=spoonycyy, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545642, encodeId=6b651545642d4, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55770, encryptionId=4dd155e701f, topicName=抗血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608413807146, createdName=12498bd5m20暂无昵称, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-23 spoonycyy

    #细胞瘤#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1753311, encodeId=dc611e53311b2, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Sep 17 22:43:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932957, encodeId=22b0193295e69, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55766, encryptionId=6b1255e66ba, topicName=抗血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Feb 22 22:43:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288234, encodeId=b427128823420, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364248, encodeId=4d69136424810, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389188, encodeId=40c41389188e7, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475854, encodeId=0aea14e585489, content=<a href='/topic/show?id=2bcee797732' target=_blank style='color:#2F92EE;'>#细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77977, encryptionId=2bcee797732, topicName=细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5e7252474, createdName=spoonycyy, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545642, encodeId=6b651545642d4, content=<a href='/topic/show?id=4dd155e701f' target=_blank style='color:#2F92EE;'>#抗血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55770, encryptionId=4dd155e701f, topicName=抗血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608413807146, createdName=12498bd5m20暂无昵称, createdTime=Mon Oct 23 06:43:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-23 12498bd5m20暂无昵称

    #抗血管生成#

    0

相关资讯

JAMA：成胶质细胞瘤放疗联合替莫唑胺可延长一倍生存期

典型恶性成胶质瘤的磁共振成像特征 研究要点： 1.仅有辐射暴露和特定的遗传综合征是明确的恶性胶质瘤风险因子； 2.新诊成胶质细胞瘤的治疗是基于放疗合并替莫唑胺。这一临床路径使患者的2年生存率倍增达到27%，然而总体预后仍不良；贝伐单抗是一种值得进一步研究的新兴替代药物； 3.恶性胶质瘤患者常伴频繁的并发症，包括血栓事件、癫痫、神经病症状反复发

CANCER RES：成胶质细胞瘤潜在治疗位点

北海道大学研究发现新的成胶质细胞瘤潜在治疗靶点